Pergolide mesylate acts as an ergot dopamine receptor agonist at both D1 and D2 receptor sites in the brain that control the production of dopamine within the hypothalamus.

Controls adrenal secretions of glucocorticoid hormones characteristic of ECS.

Product is registered by the APVMA for the treatment of ECS.

Supported by an extensive clinical trial program.

DIRECTIONS FOR USE/CONTRAINDICATIONS
Administer orally over the tongue once daily. Consult your veterinarian before altering the dosage. If the dosage is to be increased it is recommended that 0.5mg increments be assessed before higher daily doses are employed.

IMPORTANT NOTE: ECS is a disease which is managed, not cured and therefore lifelong treatment is required for affected horses. For best results pharmaceutical therapy should be employed in adjunct with nutritional strategies. Retraction of Ranvet’s Pergolide therapy will cause re-establishment of clinical signs within 7-10 days.

DOSAGE RATES
5mL/500kg bodyweight (0.002mg/kg bodyweight) once daily. Each 5mL dose provides 1mg pergolide mesylate. The daily dose may be gradually increased as directed by a veterinarian if clinical improvement fails to occur after one to two months of therapy.

PACK SIZE(S)
200mL